Most Read Articles
Stephen Padilla, 6 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
06 Aug 2020
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Stephen Padilla, 2 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.

Docetaxel without prednisone ineffective for preventing prostate cancer progression after RT

28 Nov 2019

In prostate cancer patients who had undergone radical radiotherapy (RT), adjuvant docetaxel does not improve biochemical disease-free survival in the absence of prednisone, a recent study has found.

Researchers randomly assigned 376 prostate cancer patients to undergo either six cycles of adjuvant docetaxel (75 mg/m2 every 3 weeks; n=188; median age, 67 years) without continuous prednisone or surveillance (n=188; median age 67 years). The primary endpoint was increasing prostate-specific antigen (PSA) levels 2 ng/mL above the nadir value.

After 104 months since randomization, 58 docetaxel-treated patients and 57 surveillance controls had fulfilled the study endpoint of PSA progression 2.0 ng/mL above nadir. The median time to progression, death or last follow-up in the respective treatment arms was 60 and 59 months.

Kaplan-Meier analysis revealed no significant difference in the risk of progression over time between the two treatment groups (p=0.6). The 5-year biochemical progression rate estimates were 31 percent for the docetaxel group and 28 percent for the surveillance group.

Forty-three deaths occurred during the trial, 20 of which were in the docetaxel arm and 23 were in the surveillance arm. Nine and seven, respectively, were related to prostate cancer. The resulting 5-year estimated mortality rate was 10 percent for both groups.

Cox multivariate analysis further confirmed the null effect of treatment arm assignment on PSA progression (docetaxel vs surveillance: hazard ratio, 1.14, 95 percent confidence intervals, 0.79–1.64; p=0.5).

“Our result does not support the use of docetaxel after radical RT for intermediate- or high-risk prostate cancer,” said researchers.

Editor's Recommendations
Most Read Articles
Stephen Padilla, 6 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
06 Aug 2020
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Stephen Padilla, 2 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.